Webinar
Join us on November 5 for a practical session on using SR&ED, grants and other non-dilutive funding to support R&D, validation, and commercialization in Canada by OBIO® member PeakR&D.
Extend your runway and reach your next milestone with less equity dilution by treating non-dilutive capital as a strategic, multi-year component of your funding strategy, rather than a series of one-off applications.
The session will cover:
What non-dilutive funding is available for life sciences and health tech companies at different stages
How to identify the right programs and combine SR&ED, grants, and other funding opportunities
What funders and SR&ED reviewers look for, and common mistakes that can lead to delays, reductions or rejections
Who should attend:
Canadian life sciences and health tech companies across different stages of development, from early R&D and validation through regulatory milestones, commercialization, and scale-up.
Founders and CEOs setting growth and funding strategy
CFOs and finance leaders managing R&D budgets, tax credits, and cash planning
R&D, scientific and innovation leaders planning R&D projects and milestones
The meeting invite and details will be included in the registrants' confirmation email.